Merck Gets EC Approval For Keytruda Regimens in Head, Neck Cancer

Date : 11/20/2019 @ 12:36PM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 88.85  0.1 (0.11%) @ 12:59AM
After Hours
Last Trade
Last $ 88.91 ▲ 0.06 (0.07%)

Merck Gets EC Approval For Keytruda Regimens in Head, Neck Cancer

Merck (NYSE:MRK)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Merck Charts.

By Colin Kellaher

 

Merck & Co. (MRK) on Wednesday said the European Commission approved two new regimens of its cancer drug Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma.

The Kenilworth, N.J., drug maker said the approval includes Keytruda as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy, for the first-line treatment of patients whose tumors express PD-L1.

Merck said the approval is based on a phase 3 study in which Keytruda, compared with standard treatment, showed a significant improvement in overall survival as monotherapy and in combination with chemotherapy in such patients.

The company said Keytruda is the first anti-PD-1 treatment option approved in Europe in the first-line setting for metastatic or unresectable recurrent head and neck cancer.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 20, 2019 07:21 ET (12:21 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.